Mycoplasma Testing Market Trends

Growth Drivers

• Rising Concern Associated with Cell Culture Contamination – Mycoplasma is the bacteria that contaminate the cell culture, and mycoplasma testing is an essential step in preventing cell contamination and its detrimental effects on the research. According to FDA, ATCC, and other research, around 5 - 30% of all cell cultures nowadays are infected with mycoplasma species solely. In a single case, the prevalence of viral contamination of popular cell lines topped 25%.
• Increasing Spending in Pharmaceutical R&D Activities– Increased expenditure leads to more complex and advanced research projects, as the complexity of cell culture increases the need for mycoplasma testing also rises as a part of the quality control measure.  Global R&D spending in pharmaceutical studies reached around 238 billion US dollars in 2021.
• Technological Advancement in Mycoplasma Testing –Technology innovation has improved the efficiency accuracy and accessibility of mycoplasma testing, thus bringing lucrative opportunities for the industry. For instance, Sartorius developed a Micorsart Mycoplasma qPCR detection assay that enables early detection of contamination of even non-culturable mycoplasma.

Challenges

• High Cost of Mycoplasma Testing- Many research laboratories and academic institutions often have limited budgets, and the high cost of mycoplasma testing can stain its usage and hamper the market growth. For instance, the cost of a biological sample is around USD 125, and the cost of a patient specimen is nearly USD 210.
• Lack of skilled technicians
• Higher Loyalty to Existing Brand is Limiting the Opportunity for New Entrants